Resumen
Precision oncology is gaining a great deal of interest as it aims to administer the right drug to the right patient at the right moment, overcoming the classical paradigm of ?one drug fits all?. Molecular tumor boards (MTBs) are multidisciplinary groups instituted to formulate the most up-to-date therapeutical or diagnostic indication for cancer patients performing genomic analyses. Unfortunately, MTBs must face many issues in applying the indications formulated and only a small percentage of patients effectively receives the targeted treatment. In this review, we aim to describe the most common issues that impede the implementation of MTB indications and the solutions that have been developed.